Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN HIVES RELIEF versus CLARITIN REDITABS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN HIVES RELIEF versus CLARITIN REDITABS.
CLARITIN HIVES RELIEF vs CLARITIN REDITABS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inverse agonist at histamine H1 receptors, blocking histamine-mediated effects in allergic reactions.
Loratadine is a selective antagonist of peripheral histamine H1 receptors, reducing allergic response symptoms by inhibiting histamine release from mast cells.
10 mg orally once daily
10 mg orally once daily.
None Documented
None Documented
8.4 hours (range 3-20 hours) for loratadine; 28 hours (range 8.8-92 hours) for active metabolite desloratadine, allowing once-daily dosing.
Terminal elimination half-life: 8–28 hours (mean ~14 hours for loratadine; active metabolite desloratadine: 14–26 hours). Context: Allows once-daily dosing; half-life extended in hepatic impairment.
Renal: ~40% as metabolites, <1% unchanged; Fecal: ~40%; Biliary: minor contribution.
Renal (approximately 40% as metabolites) and fecal (approximately 40% as metabolites). Parent drug and active metabolite (desloratadine) are excreted in urine (27% total) and feces (40% total).
Category C
Category C
Antihistamine
Antihistamine